Learn to Rank Images: A Unified Probabilistic Hypergraph Model for Visual Search by Zeng, Kaiman et al.
Florida International University
FIU Digital Commons
Electrical and Computer Engineering College of Engineering and Computing
6-16-2016
Learn to Rank Images: A Unified Probabilistic
Hypergraph Model for Visual Search
Kaiman Zeng
Department of Electrical and Computer Engineering, Florida International University, kzeng001@fiu.edu
Nansong Wu
Department of Electrical and Computer Engineering, Florida International University, nwu@fiu.edu
Arman Sargolzaei
Department of Electrical and Computer Engineering, Florida International University, asargolz@fiu.edu
Kang Yen
Department of Electrical and Computer Engineering, Florida International University, yenk@fiu.edu
Follow this and additional works at: http://digitalcommons.fiu.edu/ece_fac
Part of the Materials Science and Engineering Commons, and the Mechanical Engineering
Commons
This work is brought to you for free and open access by the College of Engineering and Computing at FIU Digital Commons. It has been accepted for
inclusion in Electrical and Computer Engineering by an authorized administrator of FIU Digital Commons. For more information, please contact
dcc@fiu.edu.
Recommended Citation
Kaiman Zeng, Nansong Wu, Arman Sargolzaei, and Kang Yen, “Learn to Rank Images: A Unified Probabilistic Hypergraph Model for
Visual Search,” Mathematical Problems in Engineering, vol. 2016, Article ID 7916450, 7 pages, 2016. doi:10.1155/2016/7916450
Research Article
90Y-DOTA-CHS Microspheres for Live
Radiomicrosphere Therapy: Preliminary In Vivo Lung
Radiochemical Stability Studies
Alejandro Amor-Coarasa,1 Andrew Milera,2 Denny Carvajal,3,4
Seza Gulec,2,3,5 and Anthony J. McGoron2,3
1 Department of Radiology, Weill Cornell Medical College, New York City, NY 10028, USA
2Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33174, USA
3 Biomedical Engineering Department, Florida International University, Miami, FL 33174, USA
4Mount Sinai Medical Center, Miami, FL 33140, USA
5 Jackson North Medical Center, Miami, FL 33169, USA
Correspondence should be addressed to Anthony J. McGoron; mcgorona@fiu.edu
Received 12 September 2013; Accepted 25 November 2013; Published 3 February 2014
Academic Editor: Samer Ezziddin
Copyright © 2014 Alejandro Amor-Coarasa et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Chitosan (CHS) is used to prepare microspheres of 31 ± 8 𝜇m size. Surface modification with p-SCN-Bn-DOTA was performed. A
maximum 90Y capacity was found to be 12.1 ± 4.4 𝜇Ci/particle. The best obtained labeling yield was 87.7 ± 0.6%. More than 90% in
vitro stability was found. Particle in vitro degradation half-life in PBS was found to be greater than 21 days. In vivo studies with 90Y-
DOTA-CHS showedmore than 95%of the injected activity (decay corrected) in the lungs 24 hours after tail vein administration. 90Y-
DOTA-CHS in vivo label stability was superior to resinmicrospheres.The addition of p-SCN-Bn-DOTA served as a radioprotectant
for bone marrow as the 5% 90Y released, during the first 24 hours, was quickly eliminated via urine.
1. Introduction
In 2010 new cases of primary liver and intrahepatic bile duct
cancer in the USA reached 24120, with 18910 deaths. New
colorectal cancer cases reached 142570 with 51370 deaths,
nearly half of the latter becoming metastatic liver cancer
[1]. Liver cancer (primary or metastatic) accounts for nearly
10% of all cancers in the USA with incidence being even
greater in eastern countries. Treatment modalities involve
surgery [2], chemotherapy [3], chemoembolization [4], ther-
mal ablation using radiofrequency or microwave probes
[5, 6], and Radiomicrosphere Therapy (RMT) [7, 8]. The
current RMT, also called Selective Internal Radiomicrosphere
Treatment (SIRT), is indicated for patients with unresectable
liver cancer, especially hepatic cell carcinoma and metastatic
liver cancer [8]. RMT in combination with chemotherapy,
also known as chemo-RMT, has been proposed to improve
patient outcomes [9, 10]. The sphere size (≈30 𝜇m) is 3 times
larger than the smallest blood vessel diameter (≈10 𝜇m),
which assures the deposition of these particles as the arterial
branches decrease in size. The narrow particle size distribu-
tion is necessary so that particles do not escape and pass
into the venous circuit. Further, the microvascular density of
liver tumors is 3–200 times greater than the surrounding liver
parenchyma, making the tumor allocation preferential with
respect to normal tissue [10].
The treatment progresses through several stages. When
the patient is admitted several studies are performed includ-
ing a 18F-fluorodeoxy glucose or (18F) FDG PET-CT scan to
assess tumor viability and to evaluate lesion (cancer) extent.
A biopsy is also recommended to determine the nature
of the cancer. If RMT or chemo-RMT is indicated as the
proper treatment option, the patient is then prepared for
treatment planning. The patient is put under local anesthesia
and a catheter is inserted through the patient’s groin and
guided towards the hepatic artery via fluoroscopic imaging.
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Dyes are injected (hepatic angiogram) to identify the
branches that go to the stomach and other organs. These
branches are properly coil-embolized to prevent the particles
from moving to these areas. The angiogram also provides
valuable information about the main branches feeding the
tumor or tumors which is used for the treatment planning as
well [11]. 90Y labeled microspheres (SirTEX orTheraSpheres)
are later injected for therapy.
RMT is almost always accompanied by chemotherapy
that is administered independently of the radiotherapeu-
tic particles. Since these particles are nonbiodegradable,
chemotherapy entrapment and in situ release are not pos-
sible. Polymeric microparticles that have high in vivo 90Y
radiochemical stability to protect bone marrow and also the
capability to entrap chemotherapy drugs for simultaneous
radio/chemotherapy are needed. A better design for these
particles will most likely improve the safety and effectiveness
of the current practice of RMT. Among the many materials
available, a clear candidate for this application is Chitosan, a
chitin derivative that has been extensively studied for drug
entrapment/release and has very low (if any) in vitro and in
vivo toxicity [12]. In this preliminary study, particles were
allocated in the lungs via tail vein injection. Tail vein injection
is a surgery free procedure to assess the in vivo stability
of the 90Y-DOTA-CHS labeling (compared to liver artery
catheterization).
2. Materials and Methods
2.1. Particle Preparation and Surface Modification. Chitosan
(CHS, Sigma-Aldrich, USA) particles were prepared using
water in oil (w/o) emulsion technique. OnemL of CHS
solution (2.5%w/v solution in 2% v/v acetic acid) was added
drop wise to a round bottom flask and stirred (Corning-
Cole Palmer, USA) at 1150 rpm. The flask contained 20mL
of Toluene (Acros Organics, USA) and 100 𝜇L of Tween 80
(surfactant, Sigma-Aldrich, USA). After 15 minutes 200 𝜇L of
glutaraldehyde (25% inwater, FisherSci, USA) was added and
the emulsion was stirred for another 105min. Toluene was
finally decanted and particles were washed three times with
200-proof ethanol (Sigma-Aldrich, USA) and lyophilized
(Lab-Conco, USA). Size distribution and particle concen-
tration were done using a hemocytometer (Reichert, USA).
More than 100 particles were counted and measured for each
distribution.
A 1mg/mL solution of p-SCN-Bn-DOTA (Macrocyclics,
USA, Figure 1) was prepared in Na
2
HCO
3
/NaH
2
CO
3
buffer
(Sigma-Aldrich, USA) with a pH 9.3-9.4. Particles were re-
suspended in 1mL of the p-SCN-Bn-DOTA solution and
stirred for 4, 12, 24, or 48 hours to form the DOTA-CHS
particles. The reaction yield was evaluated using the p-SCN-
Bn-DOTA absorption peak at 224 nm with a UV/Visible
spectrophotometer (Varian/Agilent Technologies, Switzer-
land). All experiments were done in triplicate for all time
points.
2.2. 90Y Labeling and In Vitro Stability. A labeling study
was performed at two different pH values: 5 and 7. The
temperature influence on labeling was also studied using 25,
35, and 37∘C. CHSmicrospheres and resin spheres (Provided
by SirTEX, USA as unlabeled sulphonated poly(styrene-
codivinylbenzene) microspheres, not for human use) were
labeled for comparison in similar conditions. A 72-hour in
vitro stability study using PBS buffer at pH 7 was performed
to evaluate radiochemical purity (more than 50% of the total
90Y dose is deposited after 72 hours). The radiolytic effect on
the CHSmicrospheres due to the presence of 90Ywas studied
during a 21-day degradation study.
Using stable YCl
3
(Sigma-Aldrich, USA) as carrier for the
radioactive 90YCl
3
(Perkin-Elmer, USA), a radioactive indi-
cator experiment was performed to calculate the maximum
90Y capacity of the preparedmicrospheres. Experiments were
also performed with resin spheres for comparison. For the
in vitro work all activity measurements were made in an
AtomLab 100 Dose Calibrator (Biodex, USA).
2.3. Animal Experiments. Sprague Dawley rats (200–225
grams, 2 per time point, Harlan, USA) were anesthetized
with an Ohmeda Isotec 3 isoflurane vaporizer (GE Health-
care, USA) after being weighed. Once restrained in the
supine position (completely anesthetized) a torso X-Ray was
obtained (Belmont Acuray 071A, USA). Immediately after,
100 𝜇L (8,000–10,000 particles) of the labeled microspheres,
(90Y-DOTA-CHS or 90Y-Resin) with an activity ranging from
555 to 925 kBq (15 to 25𝜇Ci), was injected through the
lateral tail vein. Animals were imaged with noncollimated
autoradiography (in the same unaltered supine position the
X-Ray was obtained) at 10min, 12 hours, and 24 hours after
injection using a Packard Phosphorimager (Perkin Elmer,
USA). After the last image was obtained, animals were
euthanized (24 hours after injection). For all time point their
lungs, liver, spleen, heart, kidneys, ribs, and 0.2mL of blood
and urine were collected, weighed, and measured for activity
using a Cobra 5000 well counter (Packard, USA). One group
of rats received free 90Y and served as the control group.
The obtained X-Rays and the autoradiography images were
superimposed to provide anatomical and functional data.
For the collected organ measurements, an activity versus
radiation count linearity test (with known activity samples)
was performed on the gamma well counter. A test tube
(similar to the ones used in the organs) was filled with
absorbent paper soaked in water to simulate autoabsorption
of the organs. Later, a known amount of 90Y was deposited
(ranging from 2 to 5 𝜇Ci, close to the activity range found in
the organs) onto the paper and measured (𝑛 = 3 per activity
point) in the well counter. Results were linear fitted and the
correlation coefficient was found. Spectra obtained for the
lowest and highest activity points were also compared.
3. Results and Discussion
3.1. Particle Preparation and Surface Modification. The size
distribution obtained for CHS particles was an average of
30.7 ± 8.3 𝜇m. After the preparation of the microspheres, the
DOTA decoration reaction was performed (Figure 1).
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Figure 1: CHS-p-SCN-Bn-DOTA reaction.
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Figure 2: p-SCN-Bn-DOTA-CHS reaction kinetics. Particle surface
saturation when 1mg total p-SCN-Bn-DOTA is added to the CHS
microparticles (≈100,000 in 1mL).
The kinetic study for the reaction showed that saturation
is reached at 12 hours (optimum reaction time), with no extra
attachment of p-SCN-Bn-DOTA toCHSg after 24 or 48 hours
(Figure 2).The total p-SCN-Bn-DOTA-CHS reaction yield is
around 25% (with a maximum 250 𝜇g of p-SCN-Bn-DOTA
addition). The approximated 6.3mg of CHS (total mass of
100,000 particles, 63 ng/particle) present in each preparation
accounts for 2.33⋅1019 available NH
2
groups in total. However,
only a fraction of these groups are exposed to themicrosphere
surface and, to further complicate the problem, the surface is
irregular.
After the p-SCN-Bn-DOTAdecoration a size distribution
of 31.3 ± 8.1 was obtained.The CHSmicrosphere distribution
and morphology were not significantly changed by the p-
SCN-Bn-DOTA addition reaction (Figure 3).This is expected
due to the high pH (9.4) in which the reaction is being held
and the already low solubility and slow degradation rate of
CHS microspheres.
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Figure 3: CHS microsphere size distribution before and after p-
SCN-Bn-DOTA addition reaction.
3.2. 90Y Labeling and In Vitro Stability. Even though high
labeling yields for 90Y-CHS (99% yields) were previously
reported by our group [13], p-SCN-Bn-DOTA was used to
decorate the particle surface since the DOTA addition has
the potential to increase in vivo stability and protect the bone
marrow from 90Y leaching. Maximum labeling yield for 90Y-
DOTA-CHS labeling was 87.7 ± 0.6%, obtained at pH = 7
and 37∘C (Figure 4) after 30 minutes. Yield was dependent
on both pH and temperature (Figure 4). A rise in temperature
might improve the labeling; however CHS is a polysaccharide
very sensitive to high temperature; thus structural damage
might occur. A longer labeling time did not increase the yield.
Labeling of resin spheres (Provided by SirTEX, USA as unla-
beled sulphonated poly(styrene-codivinylbenzene)) showed
more than 98% yield in all conditions within 10 minutes of
the start of the reaction. The labeling was performed at pH =
7 only since resin spheres are typically labeled and injected in
water. Yield was not dependent on temperature for the range
studied.
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Figure 4: Labeling yields for 90Y-CHS, 90Y-DOTA-CHS, and 90Y-
Resin at different pH values and temperatures.
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Figure 5: In vitro stability study for 90Y-DOTA-CHS and 90Y-Resin.
The in vitro stability was over 90% for 90Y-DOTA-CHS
after 72 hours compared to the 80% obtained for the resin
spheres (Figure 5). Considering these positive results for 90Y-
DOTA-CHS, animal experiments were performed.
The extended in vitro degradation of the particles showed
that particle integrity was maintained, although some surface
degradation is seen after 21 days (Figure 6). This timeframe
was chosen since more than 95% of the 90Y is physically
decayed by 21 days.Theobtained biodegradablemicrospheres
demonstrated a long enough half-life to adequately perform
RMTwhile allowing for ultimate particle clearance and blood
flow restoration.
Finally, the maximum labeling capacity for the CHS-p-
SCN-Bn-DOTAmicrospheres was 12.1 ± 4.4 𝜇Ci/particle and
for resin spheres 111.7 ± 0.1 𝜇Ci/particle. Hence, in a regular
treatment course using 3⋅106 to 30⋅106 particles, maximum
possible activity load is 36–360Ci and 335.1–3351 Ci for CHS-
p-SCN-Bn-DOTA and resin spheres, respectively. These val-
ues are 3 orders of magnitude over the regular administered
dose (30–100mCi, [10]).
3.3. Animal Experiments. Detector linearity response
to activity and spectra distribution were performed as
described. A high correlation coefficient (𝑅 = 0.996) was
obtained.
The high specific gravity of the resin spheres makes
particle injection difficult since they deposit fast. An injection
yield (% of the total loaded to the syringe that is actually
injected) of only 15% was reached (injected in water). The
injection yield for the 90Y-DOTA-CHS microspheres was
over 50% (injected in saline solution). The initial assessment
of biodistribution with a survey meter (Victoreen ASM-990,
Fluke, USA) revealed a strong allocation in the lungs for
the 90Y-DOTA-CHS microspheres while the resin spheres
distribution did not differ from the free 90Y. This was
interpreted to indicate that the 90Y has disassociated from the
resin particles as they moved through the vena cava, through
the heart and into the lungs. For 90Y-Resin and free 90Y the
10 minutes autoradiography images showed strong 90Y bone
marrow and kidney allocation (Figure 7). However, organ
quantification (Cobra 5000 well counter, Packard, USA) at 24
hours showed some lung allocation for 90Y-Resin (Table 1).
Lung allocation of more than 95% of the injected activity
(decay corrected) was detected for 90Y-DOTA-CHS after 24
hours, showing a significant difference with the 23% found
for the 90Y-Resin. Free 90Y was initially allocated in the bone
marrow but only 9% remained after 24 hours. The rest of the
activity was eliminated via urine. Over 4% of the injected 90Y-
Resin activity was found in bone marrow after 24 hours and
more than 70% was eliminated by then. In contrast to this
result the activity released from the lungs in the 90Y-DOTA-
CHS experiments resulted in only a fraction of a percent
being allocated to the bone marrow, and the remaining was
located in either the urine or was already eliminated.
The attachment of p-SCN-Bn-DOTA to CHS for the
90Y-DOTA-CHS labeling dramatically improves the in vivo
stability of the drug product. Furthermore the strong 90Y-
DOTA chelation did not release free 90Y to the blood stream.
The released particle degradation products (presumably as
90Y-DOTA-Fragments) acted as a radioprotector of the bone
marrow and other organs by being quickly eliminated to the
urine.
The collected organs for the 90Y-Resin and free 90Y
showed a very similar picture. Major damage to the kidneys
was observed with low urine output and significant swelling.
In the case of 90Y-Resin the lungs were a bit discolored
and swollen because of some radiation damage (due to the
Journal of Radiotherapy 5
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Figure 6: Degradation of 90Y-CHS microspheres after (a) 1 day, (b) 7 days, (c) 14 days, and (d) 21 days.
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Figure 7: Non decay-corrected, un-collimated full body X-Ray/Autoradiography for 90Y-DOTA-CHS, 90Y-Resin and free 90Y at 10 minutes,
12 and 24 hours.
allocation of 23% of the decay corrected injected activity at 24
hours). For the 90Y-DOTA-CHS microspheres the radiation
damage distribution was completely different.The lungs were
significantly discolored and fragile after 24 hours (due to the
allocation of more than 95% of the decay corrected injected
activity at 24 hours) while no visible damage was seen in the
kidneys and normal urine output was observed. Note that
systemic venous injection of 90Y microspheres so that they
locate in the lungs would never be therapeutically indicated.
Thismodel was used only to investigate in vivo radiochemical
stability and animals were not allowed to survive longer than
24 hours because of the organ damage that was expected to
occur.
4. Conclusion
CHS microspheres within the 30 ± 10 𝜇m size range were
successfully obtained. Surface modification of CHS micro-
spheres with p-SCN-Bn-DOTA was accomplished with an
optimal reaction time of 12 hours.The surface decoration did
not affect the original size distribution or morphology. Max-
imum 90Y capacity was found to be 12.1 ± 4.4 𝜇Ci/particle,
whichmeans thatwhenusing 3⋅106 to 30⋅106 particles (normal
therapeutic range) maximum possible activity load is 36–
360Ci (orders of magnitude higher than actual activities
used). Maximum obtained labeling yield was 87.7 ± 0.6%
when labeling at pH = 7 and 37∘C for 30 minutes. More
than 90% in vitro stability was found in reconstituted 1%
6 Journal of Radiotherapy
Table 1: Biodistribution for 90Y-CHS, 90Y-Resin, and free 90Y at 24 hours expressed as percent of decay corrected injected dose per organ
(% DC-ID/o).
Organs
Biodistribution in % DC-ID/o
90Y-CHS 90Y-Resin Free 90Y
24 hours 24 hours 24 hours
Spleen 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
Blood 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
Total bone marrow 0.3 ± 0.0 4.5 ± 1.2 9.0 ± 0.4
Urine 0.9 ± 0.1 0.3 ± 0.0 0.4 ± 0.3
Right kidney 0.1 ± 0.0 0.6 ± 0.1 1.3 ± 1.0
Left kidney 0.1 ± 0.0 0.6 ± 0.1 0.7 ± 0.1
Heart 0.2 ± 0.1 0.1 ± 0.0 0.1 ± 0.0
Total lungs 95.4 ± 1.6 23.0 ± 4.3 0.2 ± 0.0
Total liver 0.3 ± 0.0 1.1 ± 0.3 1.8 ± 0.1
Eliminated 2.6 ± 1.4 69.7 ± 2.6 86.4 ± 1.3
hemoglobin lysate after 72 hours. Particle in vitro degradation
half-life in PBS was found to be greater than 21 days. In
vivo studies with 90Y-DOTA-CHS labeledmicrospheres show
remarkable stability with more than 95% of the injected
activity (decay corrected) still in the lungs after 24 hours. 90Y-
DOTA-CHS performance was superior to the commercially
available resin microspheres with only 23% of the injected
activity (decay corrected) in the lungs after 24 hours. Autora-
diography images obtained at 10 minutes showed strong
release of 90Y from the commercial particles. The addition
of p-SCN-Bn-DOTA served to increase labeling yield and in
vivo stability but also to act as a possible radioprotectant for
other organs since less than 1% was found in bone marrow
(regular 90Y target organ).The 5% 90Y released from the lungs
during the first 24 hours was quickly eliminated via urine.
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